Connective Tissue Diseases: Clinical Trials

4310 completed, 1150 unknown, 907 recruiting, 615 terminated. 1782 Not applicable, 1580 Phase 2, 1049 Phase 3, 1003 Phase 1, 581 Phase 4.

By phase and status

Phase	Trials	Status
Not applicable	1782	Completed 959, Unknown 314, Recruiting 184, Not yet recruiting 109, Terminated 83, Active not recruiting 74, Withdrawn 38, Enrolling by invitation 17, Suspended 4
Phase 2	1580	Completed 873, Terminated 214, Recruiting 162, Unknown 133, Not yet recruiting 65, Active not recruiting 63, Withdrawn 57, Enrolling by invitation 8, Suspended 5
Phase 3	1049	Completed 664, Terminated 100, Unknown 90, Recruiting 75, Active not recruiting 60, Withdrawn 25, Not yet recruiting 21, Enrolling by invitation 13, Suspended 1
Phase 1	1003	Completed 538, Recruiting 164, Terminated 90, Unknown 70, Not yet recruiting 47, Withdrawn 42, Active not recruiting 40, Enrolling by invitation 6, Suspended 6
Phase 4	581	Completed 326, Unknown 100, Terminated 57, Recruiting 46, Withdrawn 20, Active not recruiting 15, Not yet recruiting 14, Enrolling by invitation 3
Early Phase 1	112	Recruiting 30, Completed 25, Unknown 20, Not yet recruiting 17, Terminated 7, Withdrawn 6, Active not recruiting 4, Suspended 2, Enrolling by invitation 1

Follow Connective Tissue Diseases: new trials by email Literature Review of Connective Tissue Diseases trials Research Report on Connective Tissue Diseases

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Cannabichromene Safety in Rheumatoid Arthritis Cannabichromene - Arthritis, Rheumatoid	Phase 1 / Phase 2	Withdrawn	Crystal Lederhos Smith		2028-07-15	2026-09-23
An Open-label Study of GC012F in Rheumatoid Arthritis. LD and GC012F CAR-T Cell Injection, GC012F CAR-T Cell Injection - Rheumatoid Arthritis	Early Phase 1	Withdrawn	Institute of Hematology & Blood Diseases Hospital, China		2027-12-01	2026-06-10
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) CB-010 - Systemic Lupus Erythematosus, Lupus	Phase 1	Withdrawn	Caribou Biosciences, Inc.		2027-12-01	2025-09-19
Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy: Baby MERIT Trametinib - HCM, Noonan Syndrome and Other Rasopathy	Phase 3	Not yet recruiting	Carelon Research	25	2027-08-01	2026-09-14
An Exercise and Lifestyle Programme for Adults With Vascular Ehlers-Danlos Syndrome: A Feasibility Study Co-designed exercise-based lifestyle intervention - Vascular Ehlers Danlos Syndrome	Not applicable	Not yet recruiting	Sheffield Hallam University	40	2027-03-01	2026-07-13
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy C-CAR168 - Systemic Sclerosis (SSc), Systemic Sclerosis	Phase 1	Not yet recruiting	AbelZeta Inc.	12	2027-03-01	2026-10-13
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis BMS-986353, Fludarabine, Cyclophosphamide - Systemic Sclerosis	Phase 3	Not yet recruiting	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	92	2027-02-03	2026-09-18
A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP) garetosmab - Fibrodysplasia Ossificans Progressiva, FOP	Phase 3	Not yet recruiting	Regeneron Pharmaceuticals	18	2027-02-02	2026-11-12
Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress TEAM-LEADS - Lupus, Dermatomyositis, Juvenile	Not applicable	Not yet recruiting	Duke University	25	2027-02-01	2026-05-27
The Primary Objective of the Trial is to Evaluate the Effect of the Addition of Belantamab Mafodotin to Standard of Care Therapy on the Titres of Serum Anti-dsDNA Antibodies in Patients With Previously Treated SLE. belantamab mafodotin to the existing stable standard background therapy - SLE - Systemic Lupus Erythematosus	Phase 2	Not yet recruiting	Medical Association for the Study of Cancer Biology and Treatment	12	2027-02-01	2026-09-28
Efficacy and Safety Study of L608 in Patients With Systemic Sclerosis-associated Digital Ulcers L608, Placebo - Systemic Sclerosis	Phase 2	Not yet recruiting	Pharmosa Biopharm Inc.	40	2027-02-01	2026-11-09
Effectiveness and Safety of Cellbooster Glow in Healthy Subjects Injectable - Wrinkle Appearance, Skin Hydration in Healthy Volunteers	Not applicable	Not yet recruiting	Suisselle	60	2027-02-01	2026-11-10
Single Injection of rAAV9-CMV-hNAGLUop Gene for Patients With Mucopolysaccharidosis (MPS) IIIB rAAV9-CMV-hNAGLUop - Sanfilippo Syndrome (MPS III)	Phase 1 / Phase 2	Not yet recruiting	NeuroGT	9	2027-01-18	2026-09-14
Regenerative Medicine for Joint Hypermobility and Instability Dextrose 20% Prolotherapy, Autologous Platelet-Rich Plasma, Doxycycline Hyclate Injectable (Investigational) - Ehlers-Danlos Syndrome Hypermobility Type (hEDS), Ehlers-Danlos Syndrome (EDS)	Phase 1 / Phase 2	Not yet recruiting	Manhattan Pain Medicine, PLLC	100	2027-01-15	2026-10-06
Improving Management and Secondary Prevention Through Azithromycin Comparative Trial in Rheumatic Heart Disease in Nigeria)- IMPACT-RHD Nigeria Benzathine Penicillin, Azithromycin (Azithro) - Rheumatic Fever, Valvular Heart Diseases	Not applicable	Not yet recruiting	Ladoke Akintola University of Technology, Ogbomoso, Nigeria	474	2027-01-05	2026-06-04
FIBROmyalgia: Somatic Tracking and Exercise Program Study Group exercising, Somatic tracking, General activity recommendaitons - Fibromyalgia (FM), Fibromyalgia	Not applicable	Not yet recruiting	University of Tromso	200	2027-01-01	2025-05-13
Patient-Reported Outcomes Dashboard With Goal Setting to Support Shared Decision-Making in Inflammatory Arthritis Patient-Reported Outcomes Dashboard With Goal Setting - Arthritis, Psoriatic (PsA), Arthritis, Rheumatoid (RA)	Not applicable	Not yet recruiting	Northwestern University	160	2027-01-01	2026-10-15
Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI) Bone marrow-derived mesenchymal stromal cells (MSCs) - Osteogenesis Imperfecta, Osteogenesis Imperfecta Type III	Phase 1 / Phase 2	Not yet recruiting	Emory University	12	2027-01-01	2026-05-08
Penn SICCA Follow-up Study Dry Eye, Sjogren's Syndrome		Not yet recruiting	University of Pennsylvania	220	2027-01-01	2026-03-02
Role of Interleukin 18 (IL-18) and Interleukin 18 Binding Protein (IL-18BP) in the Diagnostic Work-up of Systemic Juvenile Idiopathic Arthritis and Autoinflammatory Diseases: Possible Biomarkers in the Differential Diagnosis of Other Febrile Diseases Systemic Juvenile Idiopathic Arthritis (sJIA)		Not yet recruiting	IRCCS Azienda Ospedaliero-Universitaria di Bologna	9	2027-01-01	2026-03-12

Showing 20 of 8022. Sign in to see all of them.

Narrower conditions

Arthritis, Rheumatoid (3290)  ·  Lupus Erythematosus, Systemic (1188)  ·  Scleroderma, Systemic (601)  ·  Arthritis, Juvenile (359)  ·  Arthritis (338)  ·  Lupus Nephritis (336)  ·  Sjogren's Syndrome (322)  ·  Scleroderma, Diffuse (310)  ·  Osteoarthritis (283)  ·  Autoimmune Diseases (255)  ·  Rheumatic Diseases (251)  ·  Arthritis, Psoriatic (195)  ·  Dermatomyositis (181)  ·  Cellulitis (157)

Broader conditions

Skin and Connective Tissue Diseases (8017)  ·  Immune System Diseases (5223)  ·  Autoimmune Diseases (4968)  ·  Musculoskeletal Diseases (4798)  ·  Joint Diseases (3994)  ·  Rheumatic Diseases (3957)  ·  Arthritis (3730)  ·  Skin Diseases (1719)  ·  Pathological Conditions, Signs and Symptoms (1331)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1112)  ·  Pathologic Processes (944)  ·  Genetic Diseases, Inborn (903)  ·  Nervous System Diseases (686)  ·  Bone Diseases (681)

Interventions

Methotrexate (319)  ·  tocilizumab (207)  ·  Adalimumab (172)  ·  Etanercept (158)  ·  Rituximab (138)  ·  Abatacept (115)  ·  Infliximab (98)  ·  Cyclophosphamide (93)  ·  tofacitinib (91)  ·  Blood Specimen Collection (89)  ·  Mycophenolic Acid (84)  ·  Certolizumab Pegol (69)  ·  Prednisone (68)  ·  belimumab (65)  ·  Exercise (59)

Sponsors

Hoffmann-La Roche (212)  ·  Pfizer (153)  ·  Assiut University (129)  ·  Bristol-Myers Squibb (117)  ·  Amgen (99)  ·  Assistance Publique - Hôpitaux de Paris (95)  ·  GlaxoSmithKline (91)  ·  Novartis Pharmaceuticals (90)  ·  AstraZeneca (78)  ·  AbbVie (61)  ·  Zimmer Biomet (58)  ·  National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (53)  ·  Eli Lilly and Company (51)  ·  Sohag University (44)  ·  University Hospital, Montpellier (44)

Countries

United States (2780)  ·  France (1009)  ·  Germany (794)  ·  China (745)  ·  United Kingdom (736)  ·  Spain (654)  ·  Canada (618)  ·  Italy (569)  ·  Poland (552)  ·  Mexico (423)  ·  Turkey (Türkiye) (394)  ·  South Korea (388)  ·  Brazil (372)  ·  Hungary (366)  ·  Argentina (358)

Results publications

PMID 33687069, PMID 36600185, PMID 36601090, PMID 36931693, PMID 36526796, PMID 32816215, PMID 33127856, PMID 34870800, PMID 28143815, PMID 39192350, PMID 25047021, PMID 27338778, PMID 38958913, PMID 29244149, PMID 30649524, PMID 37453736, PMID 26275429, PMID 33263165, PMID 34706874, PMID 37528520, PMID 29463520, PMID 34041702, PMID 34628605, PMID 34741731, PMID 31610021, PMID 33874971, PMID 36205910, PMID 37747626, PMID 28941219, PMID 30177460, PMID 34531304, PMID 35577477, PMID 36715850, PMID 36754548, PMID 36814062, PMID 37308218, PMID 37945286, PMID 37982966, PMID 38775637, PMID 40875187, PMID 22491018, PMID 27889300, PMID 29949132, PMID 30219772, PMID 30842122, PMID 33057725, PMID 33059710, PMID 33115760, PMID 34921355, PMID 36125701

NIH funding

2023 (69), 2015 (54), 2016 (44), 2009 (39), 2018 (38), 2019 (37), 2014 (35), 2025 (35), 2017 (32), 2008 (29), 2005 (13), 2004 (8), U54NS065768 (7), P60AR047782 (4), P30AG064199 (2)